Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASIM ROY

Allopathic & Osteopathic Physicians Internal Medicine Sleep Medicine

NPI
1639159767
CMS profile
164384
Location
DUBLIN, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$129,957.60

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
JAZZ PHARMACEUTICALS INC. $63,623.62 51
HARMONY BIOSCIENCES LLC $32,574.76 32
Inspire Medical Systems, Inc. $28,656.84 4
Eisai Inc. $4,854.45 11
Itamar Medical Inc $117.87 1
Regeneron Healthcare Solutions, Inc. $95.65 1
ARBOR PHARMACEUTICALS, INC. $34.41 2

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASIM ROY

NPI 1639159767 · CMS profile ID 164384

Allopathic & Osteopathic Physicians / Internal Medicine / Sleep Medicine

DUBLIN, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159767?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASIM ROY, NPI 1639159767, CMS profile ID 164384. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159767?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ASIM ROY, NPI 1639159767, CMS profile ID 164384. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159767?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ASIM ROY, NPI 1639159767, CMS profile ID 164384, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1639159767?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $129,957.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $107.3008/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608303 CMS
HARMONY BIOSCIENCES LLC $23.4708/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080635 CMS
JAZZ PHARMACEUTICALS INC. $1,425.0008/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608749 CMS
HARMONY BIOSCIENCES LLC $720.0007/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080643 CMS
Inspire Medical Systems, Inc. $917.2307/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842855661 CMS
Eisai Inc. $18.2507/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817960583 CMS
JAZZ PHARMACEUTICALS INC. $14.7707/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845551299 CMS
ARBOR PHARMACEUTICALS, INC. $20.0307/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830925657 CMS
HARMONY BIOSCIENCES LLC $3,270.0006/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080579 CMS
HARMONY BIOSCIENCES LLC $80.4606/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080633 CMS
JAZZ PHARMACEUTICALS INC. $18.9406/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845593345 CMS
JAZZ PHARMACEUTICALS INC. $42.0006/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845594091 CMS
HARMONY BIOSCIENCES LLC $1,080.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080615 CMS
HARMONY BIOSCIENCES LLC $1,080.0006/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080631 CMS
Eisai Inc. $5.8106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817948657 CMS
HARMONY BIOSCIENCES LLC $1,080.0006/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080597 CMS
ARBOR PHARMACEUTICALS, INC. $14.3806/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830925637 CMS
HARMONY BIOSCIENCES LLC $1,080.0006/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080577 CMS
HARMONY BIOSCIENCES LLC $720.0005/28/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080581 CMS
Eisai Inc. $720.0005/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833759069 CMS
JAZZ PHARMACEUTICALS INC. $12.3105/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845586665 CMS
JAZZ PHARMACEUTICALS INC. $1,710.0005/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602285 CMS
JAZZ PHARMACEUTICALS INC. $10.3205/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845588627 CMS
HARMONY BIOSCIENCES LLC $1,080.0005/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080585 CMS
JAZZ PHARMACEUTICALS INC. $1,710.0005/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602283 CMS
JAZZ PHARMACEUTICALS INC. $2,500.0004/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602643 CMS
JAZZ PHARMACEUTICALS INC. $1,710.0004/27/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602281 CMS
Eisai Inc. $720.0004/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833761793 CMS
HARMONY BIOSCIENCES LLC $2,880.0004/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080613 CMS
HARMONY BIOSCIENCES LLC $119.5704/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080583 CMS
HARMONY BIOSCIENCES LLC $2,670.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080593 CMS
Eisai Inc. $13.5704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817918549 CMS
JAZZ PHARMACEUTICALS INC. $21.0304/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845584227 CMS
Eisai Inc. $720.0004/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833762177 CMS
JAZZ PHARMACEUTICALS INC. $23.7004/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845582215 CMS
JAZZ PHARMACEUTICALS INC. $570.0004/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602273 CMS
Eisai Inc. $480.0004/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833775173 CMS
JAZZ PHARMACEUTICALS INC. $1,710.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602265 CMS
Eisai Inc. $720.0003/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833759719 CMS
Eisai Inc. $16.8203/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817880889 CMS
Inspire Medical Systems, Inc. $654.0303/08/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842855657 CMS
Eisai Inc. $720.0003/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833762832 CMS
HARMONY BIOSCIENCES LLC $16.9902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080595 CMS
HARMONY BIOSCIENCES LLC $2,670.0002/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853080601 CMS
JAZZ PHARMACEUTICALS INC. $1,710.0002/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602253 CMS
JAZZ PHARMACEUTICALS INC. $14.1702/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845574929 CMS
Eisai Inc. $720.0002/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833762067 CMS
Inspire Medical Systems, Inc. $25,237.5002/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842855649 CMS
Inspire Medical Systems, Inc. $1,848.0801/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842855653 CMS
JAZZ PHARMACEUTICALS INC. $18.6001/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845575931 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114,130.04 137
PY2020 $86,387.61 89
PY2021 $129,957.60 102
PY2022 $96,693.33 77
PY2023 $73,768.01 126
PY2024 $101,056.34 145
PY2025 $64,257.33 116

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $255,036.84 158
PY2024 Principal investigator $155,770.13 165
PY2023 Principal investigator $284,380.01 126
PY2022 Principal investigator $277,857.17 34
PY2021 Principal investigator $445,267.47 47
PY2020 Principal investigator $132,058.13 23
PY2019 Principal investigator $773.95 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

158 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $26,116.76 12/31/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554195
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $63,311.85 12/31/2025 Non-covered Recipient Entity
SLEEP PRACTITIONERS LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554197
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 12/24/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447278
Principal investigator 1 Inspire Medical Systems, Inc. $100.00 12/24/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447301
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 12/24/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447313
Principal investigator 1 Inspire Medical Systems, Inc. $425.00 12/24/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447317
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 12/24/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447321
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 12/24/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447333
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 12/24/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447337
Principal investigator 1 Noctrix Health, Inc. $6,245.00 11/30/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628939
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.06 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741476
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $59.64 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741478
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741480
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.88 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741482
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.06 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741484
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.01 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741486
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.88 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741488
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.04 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741490
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.06 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741492
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $59.35 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741494
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.06 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741496
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $59.64 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741498
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.48 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741500
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741502
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741504
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.04 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741506
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.09 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741508
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741510
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.04 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741512
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.78 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741514
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741516
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.88 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741518
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.16 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741520
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.33 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741522
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $59.64 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741524
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.35 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741526
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741528
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447076
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447085
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447089
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447093
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447096
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447120
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447124
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447127
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447132
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447135
Principal investigator 1 Inspire Medical Systems, Inc. $100.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447195
Principal investigator 1 Inspire Medical Systems, Inc. $425.00 11/21/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447199
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446928
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446932
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446935
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446940
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446944
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446951
Principal investigator 1 Inspire Medical Systems, Inc. $3,200.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446961
Principal investigator 1 Inspire Medical Systems, Inc. $2,000.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446965
Principal investigator 1 Inspire Medical Systems, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446977
Principal investigator 1 Inspire Medical Systems, Inc. $425.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446981
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446986
Principal investigator 1 Inspire Medical Systems, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446991
Principal investigator 1 Inspire Medical Systems, Inc. $425.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446994
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446998
Principal investigator 1 Inspire Medical Systems, Inc. $425.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447001
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447006
Principal investigator 1 Inspire Medical Systems, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447009
Principal investigator 1 Inspire Medical Systems, Inc. $425.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447013
Principal investigator 1 Inspire Medical Systems, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447016
Principal investigator 1 Inspire Medical Systems, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447021
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 10/29/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251447024
Principal investigator 1 Alkermes, Inc. $1,500.00 10/10/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613918
Principal investigator 1 Alkermes, Inc. $615.00 10/10/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614358
Principal investigator 1 Alkermes, Inc. $1,300.00 10/10/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618221
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446814
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446821
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446826
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446829
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446832
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446836
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446838
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446843
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446848
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446853
Principal investigator 1 Inspire Medical Systems, Inc. $300.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446858
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446862
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446865
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446869
Principal investigator 1 Inspire Medical Systems, Inc. $275.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446872
Principal investigator 1 Inspire Medical Systems, Inc. $200.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446876
Principal investigator 1 Inspire Medical Systems, Inc. $350.00 10/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446880
Principal investigator 1 Inspire Medical Systems, Inc. $215.79 09/26/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE INSTITUTE
WEAR 1.5 STUDY No dispute reported 06/30/2026 1251446750
Principal investigator 1 Noctrix Health, Inc. $3,040.00 09/23/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628935
Principal investigator 1 ZOLL Respicardia, Inc. $132.50 09/22/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
ZOLL Respicardia, Inc. Registry Study No dispute reported 06/30/2026 1236586334
Principal investigator 1 Noctrix Health, Inc. $6,715.00 08/27/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628929
Principal investigator 1 ZOLL Respicardia, Inc. $3,000.00 08/25/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
ZOLL Respicardia, Inc. Registry Study No dispute reported 06/30/2026 1236586318
Principal investigator 1 ZOLL Respicardia, Inc. $1,300.00 08/25/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
ZOLL Respicardia, Inc. Registry Study No dispute reported 06/30/2026 1236586338
Principal investigator 1 ZOLL Respicardia, Inc. $2,732.00 07/24/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
ZOLL Respicardia, Inc. Registry Study No dispute reported 06/30/2026 1236586331
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,750.00 07/23/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741466
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 07/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741460
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,067.00 07/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741462
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 07/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741464
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 07/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741468
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,176.37 07/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741470
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 07/09/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741472
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 07/09/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741474
Principal investigator 1 Noctrix Health, Inc. $8,475.00 07/03/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628925
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741450
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741452
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741454
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.07 06/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741456
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.48 06/11/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741458
Principal investigator 1 Alkermes, Inc. $650.00 05/27/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613231
Principal investigator 1 Noctrix Health, Inc. $12,635.00 05/12/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628921
Principal investigator 1 Alkermes, Inc. $1,879.00 04/25/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618557
Principal investigator 1 Alkermes, Inc. $6,667.00 04/25/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620550
Principal investigator 1 ZOLL Respicardia, Inc. $165.00 04/23/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
ZOLL Respicardia, Inc. Registry Study No dispute reported 06/30/2026 1236586326
Principal investigator 1 Noctrix Health, Inc. $8,325.00 04/08/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628919
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741430
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741436
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741438
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741444
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741448
Principal investigator 1 Noctrix Health, Inc. $7,100.00 02/28/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628915
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614525
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617315
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619637
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621368
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613309
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614831
Principal investigator 1 Alkermes, Inc. $1,879.00 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614995
Principal investigator 1 Alkermes, Inc. $6,667.00 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615187
Principal investigator 1 Alkermes, Inc. $231.30 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615627
Principal investigator 1 Alkermes, Inc. $22.50 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616309
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618529
Principal investigator 1 Alkermes, Inc. $70.40 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618535
Principal investigator 1 Alkermes, Inc. $0.48 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620173
Principal investigator 1 Alkermes, Inc. $17.10 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620175
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620824
Principal investigator 1 Alkermes, Inc. $2.25 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621442
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621448
Principal investigator 1 Alkermes, Inc. $17.60 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621644
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622099
Principal investigator 1 Alkermes, Inc. $324.10 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622735
Principal investigator 1 Alkermes, Inc. $1.71 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622972
Principal investigator 1 Alkermes, Inc. $15.39 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622974
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624098
Principal investigator 1 Alkermes, Inc. $218.45 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625429
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625447
Principal investigator 1 Alkermes, Inc. $16.00 02/12/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625674
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741432
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741434
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741440
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741442
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Ohio Sleep Medicine and Neuroscience Institute
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233741446
Principal investigator 1 Noctrix Health, Inc. $6,080.00 01/17/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
THRIVE No dispute reported 06/30/2026 1254628913
Principal investigator 1 ZOLL Respicardia, Inc. $2,055.00 01/15/2025 Non-covered Recipient Entity
Ohio Sleep Medicine Institute
ZOLL Respicardia, Inc. Registry Study No dispute reported 06/30/2026 1236586321
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627108
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
OHIO SLEEP MEDICINE AND NEUROSCIENCE INSTITUTE
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627254